[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graves-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graves-disease":82},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,41,0,25,[9,45,68,94,110,137,157,182,206,229,258,293,318,342,369,389,417,443,467,491,515,539,557,583,609],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100648627","phase-2-a-study-to-learn-about-the-effects-of-felzartamab-on-thyroid-function-and-its-safety-in-adults-with-graves-disease-ages-18-to-75-years-old-100648627",false,"NCT07722546","A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old","A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab Compared to Placebo in Adult Participants With Graves' Disease","GRAVITATE","Key Inclusion Criteria:\n\n* Have active disease and are thyroid-stimulating hormone receptor antibodies (TRAb) positive, defined as:\n\n  * Free thyroxine (FT4) and free triiodothyronine (FT3), within the reference range,\n  * suppressed thyroid-stimulating hormone (TSH)\n  * TRAb levels \\> upper limit of normal (ULN)\n* Participants must be receiving stable dose of anti-thyroid drugs (ATD) for at least 12 weeks prior to randomization.\n* Must agree to refrain from blood product donation from Screening through end of study. If a participant terminates early from the study, they must refrain from blood product donation for 90 days following the last dose of study drug.\n\nKey Exclusion Criteria:\n\n* History of thyroidectomy or radioactive iodine therapy.\n* ATD dose change within 12 weeks prior to Day1, or anticipated need for dose adjustment prior to randomization (except for protocol-defined safety management).\n* Active, moderate-to-severe, or sight threatening thyroid eye disease (TED) (as assessed by the clinical activity score \\[CAS\\]), or requirement for imminent or ongoing TED-directed therapy (e.g., systemic glucocorticoids, biologic therapy, orbital radiation, surgery).\n* Any history of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.\n* History of hyperthyroidism not caused by GD (e.g. toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis) and\u002For history or presence of thyroid storm.\n* Type 1 diabetes and type 2 diabetes mellitus with hemoglobin A1c (HbA1c) \\> 8%.\n* Known or suspected history of hypersensitivity to felzartamab or its excipients.\n* Use of immunosuppressive therapy within 5 half-lives\u002F12 weeks of Screening.\n* Co-existing autoimmune diseases that require systemic immunosuppressants (e.g., cyclosporine, methotrexate, biologics, monoclonals).\n* Prior use of an anti-Neonatal Fragment Crystallizable Receptor (FcRn) therapy or intravenous immunoglobulin (IVIg) within 6 months of the last dose prior to Screening.\n* Any condition that requires chronic use of high-dose steroids.\n\nNOTE: Other protocol-defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years","75 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called thyroid-stimulating hormone receptor antibodies (TRAb), that attack the thyroid gland. This causes the thyroid to become too active and produce too much hormone, a condition called hyperthyroidism.\n\nParticipants with GD are often treated with anti-thyroid drugs, or ATDs, which are medicines that help bring thyroid hormone levels back to normal. Felzartamab is designed to target certain immune cells that produce the abnormal TRAb antibodies.\n\nThe main goal of the study is to learn whether felzartamab can help bring thyroid hormone levels back to normal and allow participants to stop taking ATDs. Participants will receive either felzartamab or placebo during the study. A placebo looks like the study drug but contains no real medicine.\n\nThe main question that researchers want to answer is:\n\n• How many participants have normal thyroid levels without receiving any ATD medicine at Week 24?\n\nResearchers will also learn more about the safety of felzartamab and how the body processes the drug.\n\nThe study will be done as follows:\n\n* Participants will be screened to check if they can join the study.\n* This is a double-blind study, which means neither the participants, study doctor, or site staff will know if participants are receiving felzartamab or a placebo.\n* Participants will be placed into 1 of 3 groups. Two groups will receive felzartamab while the other receives placebo.\n* Participants will receive felzartamab or placebo as intravenous (IV) infusions, which are slow injections into a vein using a needle. The Treatment Period will last 20 weeks.\n* During the Treatment Period, the study doctor may gradually lower the dose of the ATD if a participant's thyroid levels become normal.\n* Afterwards, participants will enter a follow-up period which will last 12 weeks.\n* In total, participants will have 22 study visits. Participants will stay in the study for about 9 months (up to 36 weeks).",[29],"Graves' Disease",[31],"Hyperthyroidism","RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2026-07-30",{"date":40,"type":23},"2028-03-31",{"name":42,"class":43},"Biogen","INDUSTRY",4,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100640696","phase-3-a-study-to-assess-efficacy-and-safety-of-efgartigimod-ph20-sc-pfs-in-adult-participants-with-graves-disease-100640696","NCT07596849","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.","A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs","VitaliThy","Inclusion Criteria:\n\n* Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.\n* Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \\>=ULN (upper limit of normal) at screening\n* Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \\\u003C0.1 mIU\u002FL at screening\n* Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter)\n* History of RAI (radioactive iodine) therapy or received a total thyroidectomy\n* T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \\\u003C6 weeks before screening\n* Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.\n* Graves' orbitopathy\u002FThyroid Eye Disease (GO\u002FTED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and\u002For planned corrective surgery\u002Firradiation or medical therapy during the study",{"count":54,"type":23},230,[56],"PHASE3","The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.\n\nThe study consists of a part A double-blinded treatment period, a part B treatment\u002Fobservation period and a part C open-label treatment\u002Fobservation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.\n\nThe total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.\n\nMore information can be found here: https:\u002F\u002Fclinicaltrials.argenx.com\u002Fvitalithy",[59],"Graves Disease",{"date":35,"type":36},{"date":62,"type":36},"2026-06-10",{"date":64,"type":23},"2030-05",{"name":66,"class":43},"argenx",12,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":4,"leadSponsor":90,"locationsCount":93},"100054236","natural-history-of-thyroid-function-disorders-100054236","NCT00001159","Natural History of Thyroid Function Disorders","* INCLUSION CRITERIA:\n\nThe categories of subjects eligible to participate in this study include:\n\n1. Patients with known or suspected thyroid abnormalities (e.g. hypothyroidism, hyperthyroidism, extreme iodine deficiency, and inherited forms of hypothyroidism resulting from abnormalities in the expression of genes coding for the TSH- beta subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS.\n2. Patients with thyroid function test (TFT) abnormalities due to:\n\n   * Non-thyroidal illness\n   * Abnormalities of serum TH binding proteins leading to euthyroid hyperthyroxinemia or hypotriiodothyronemia.\n   * Genetic deficiency of thyroxine-binding globulin (TBG).\n   * Antibodies to mouse immunoglobulins leading to an artifactual elevation in the TSH ultrasensitive (\"3rd generation\") assay which may mimic \"inappropriate\" secretion of TSH.\n\nInclusion and exclusion criteria for each group of subjects are given below.\n\nPatients with known or suspected thyroid abnormalities will be eligible to p rticipate if the individual meets all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Male or female, aged 6 months+.\n\nHyperthyroid states include but are not restricted to:\n\n1. Graves' disease (GD) thought to result from thyroid-stimulating immunoglobulins (TSIg's), a subclass of which also stimulate eye muscle and fatty tissue producing exophthalmos (Graves' ophthalmopathy), as well as the skin in the pretibial area causing pretibial myxedema (Graves' dermopathy);\n2. Subacute thyroiditis (SAT), a painful inflammation thought to result from viral infection with Coxsackie, as well as other viruses;\n3. Silent thyroiditis, a painless inflammation thought to result from autoimmune attack of thyrocytes by antimicrosomal antibodies directed against thyroid peroxidase (TPO), as well as antithyroglobulin(anti-Tg) antibodies;\n4. Single or multiple hyperfunctioning thyroid nodules of unknown etiology, probably resulting from the activation of certain thyroid oncogenes and\u002For growth factors, such as the thyrotropin (TSH) receptor (TSHR) and the a-subunit of the G protein (Ga);\n5. Iodide-induced hyperthyroidism of unknown etiology;\n6. Surreptitious administration of thyroid hormone (TH), usually present in patients with underlying psychiatric disease or occasionally related to patients with obesity and other eating disorders\n7. Trophoblastic neoplasms, thought to result from high levels of hCG secretion, which, because of its structural similarity to TSH, causes \"spillover\" of action at the TSHR level;\n8. \"Inappropriate\" secretion of TSH, which may be present either in patients with TSH- producing pituitary tumors (TSHomas) or from a non-neoplastic cause, i.e. pituitary resistance to the action of thyroid hormone (3,4).\n\nHypothyroid states include but are not restricted to:\n\n1. Primary (or thyroidal) hypothyroidism, usually resulting from auto-antibodies to thyroid proteins, such as antimicrosomal antibodies to TPO usually associated with lymphocytic (Hashimoto's) thyroiditis (HT) or atrophic thyroiditis, or blocking antibodies to the TSHR, usually in the context of non-goitrous hypothyroidism;\n2. Secondary (or pituitary) hypothyroidism, usually resulting from tumors of the pituitary of non-thyrotropic origin such, as growth hormone (GH)-secreting tumors or prolactinomas;\n3. Tertiary (or hypothalamic) hypothyroidism, usually resulting from a deficiency in the hypothalamic hormone thyrotropin-releasing hormone (TRH), either of unknown etiology or secondary to a pituitary tumor;\n4. Bio-inactive TSH, either relating to an endogenous abnormality of hypothalamic hormones or secondary to pituitary tumors (and usually related to abnormal glycosylation patterns of the TSH molecule);\n5. Generalized resistance to thyroid hormone (RTH), a disease which has been shown to be due to abnormalities in the TH receptor, c-erbA-beta (or TR- beta).\n\nThe above are the principal disorders under study, but we may also investigate other abnormalities, such as extreme iodine deficiency, and inherited forms of hypothyroidism resulting from abnormalities in the expression of genes coding for the TSH- beta subunit, Pax-8, TTF-2, Pit-I, Tg, PDS, and NIS (among others).\n\nEXCLUSION CRITERIA:\n\nThere are no exclusion criteria for subjects with known or suspected thyroid abnormalities.","6 Months","98 Years",{"count":77,"type":23},2500,"OBSERVATIONAL","Participants in this study will be patients diagnosed with or suspected to have a thyroid function disorder. These conditions may include: hypothyroidism, hyperthyroidism, thyroid hormone resistance, Graves' Dermopathy, and thyroid-stimulating hormone (TSH) secreting pituitary adenomas.\n\nThe main purpose of this study is to further understand the natural history, clinical presentation, and genetics of thyroid function disorders. Many of the tests performed are in the context of standard medical care that is offered to all patients with thyroid function disorders. In addition, blood and tissue samples may be taken for research and genetic studies.",[31,81,82],"Hypothyroidism","Grave's Disease",[31,81,82,84,85],"Natural History","Thyroid-Stimulating Hormone Secreting Pituitary Ad","2026-08-19",{"date":33,"type":36},{"date":89,"type":36},"1977-02-01",{"name":91,"class":92},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":50,"acronym":51,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":57,"conditions":102,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":108,"locationsCount":109},"100636794","phase-3-a-study-to-assess-efficacy-and-safety-of-efgartigimod-ph20-sc-pfs-in-adult-participants-with-graves-disease-100636794","NCT07570316","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease","Inclusion Criteria:\n\n* Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.\n* Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \\>=ULN (upper limit of normal) at screening.\n* Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \\\u003C0.1 mIU\u002FL at screening.\n* Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).\n* History of RAI (radioactive iodine) therapy or received a total thyroidectomy.\n* T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \\\u003C6 weeks before screening.\n* Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.\n* Graves' orbitopathy\u002FThyroid Eye Disease (GO\u002FTED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and\u002For planned corrective surgery\u002Firradiation or medical therapy during the study.",{"count":54,"type":23},[56],[29,59],"2026-08-11",{"date":105,"type":36},"2026-08-12",{"date":62,"type":36},{"date":64,"type":23},{"name":66,"class":43},22,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100594352","phase-2-a-study-to-assess-the-efficacy-safety-and-tolerability-of-imvt-1402-as-treatment-for-adult-participants-with-graves-disease-100594352","NCT07018323","A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease","A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease","Inclusion Criteria:\n\n* Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.\n* Male or female participants aged ≥ 18 years.\n* Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.\n* Other, more specific inclusion criteria are defined in the protocol.\n\nExclusion Criteria:\n\n* Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.\n* Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.\n* Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and\u002For are planning corrective surgery\u002Firradiation or medical therapy for TED during study participation.\n* Additional exclusion criteria are defined in the protocol.",{"count":118,"type":23},210,[26],"This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.",[29],[123,124,125,126,127,128],"IMVT-1402","Graves' disease","Thyroid-Stimulating Hormone Receptor","Immunoglobulin G","Antithyroid drug","Imeroprubart",{"date":105,"type":36},{"date":131,"type":36},"2025-06-19",{"date":133,"type":23},"2027-05",{"name":135,"class":43},"Immunovant Sciences GmbH",160,{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100572003","phase-2-a-study-to-assess-the-efficacy-safety-and-tolerability-of-imvt-1402-as-treatment-for-adult-participants-with-graves-disease-100572003","NCT06727604",{"count":142,"type":23},240,[26],"This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.\n\nThe primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \\[T3\\] or free triiodothyronine \\[FT3\\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.",[29],[123,147,31,148,128],"Anti Thyroid Drug","Autoimmune thyroid disease","2026-08-10",{"date":103,"type":36},{"date":152,"type":36},"2024-12-17",{"date":154,"type":23},"2028-06",{"name":135,"class":43},134,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":165,"targetDuration":167,"studyType":78,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":93},"100597516","prevalence-and-predictors-of-incidental-thyroid-carcinoma-in-patients-with-graves-disease-undergoing-thyroidectomy-100597516","NCT07059507","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy: A Prospective Study.","GD","Inclusion Criteria:\n\n* Age 18 years or older.\n* Confirmed diagnosis of Graves' disease based on clinical features (e.g., diffuse goiter, ophthalmopathy if present) and biochemical evidence (suppressed TSH, elevated free T4 and\u002For T3) and\u002For positive TSH receptor antibody (TRAb) test.\n* Indication for total thyroidectomy for Graves' disease, based on established guidelines:\n\nRelapse or persistence of hyperthyroidism after a course of antithyroid drugs (ATDs).\n\nIntolerance or adverse reaction to ATDs. Patient preference for surgery over radioactive iodine (RAI) or long-term ATDs. Presence of a large goiter causing compressive symptoms. Coexisting suspicious thyroid nodule(s) on preoperative evaluation. Moderate to severe active Graves' ophthalmopathy where RAI is relatively contraindicated.\n\n* Patient is scheduled for total thyroidectomy (near-total or subtotal thyroidectomy patients will be excluded).\n* Ability and willingness to provide written informed consent.\n* Ability to understand study procedures and requirements.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Previous thyroid surgery.\n* Previous neck irradiation.\n* Preoperative diagnosis of thyroid malignancy confirmed by fine-needle aspiration (FNA) cytology (Bethesda V or VI) , the focus is on incidental carcinoma.\n* Inability to provide informed consent (e.g., due to cognitive impairment).\n* Patients undergoing thyroidectomy primarily for reasons other than Graves' disease (e.g., primary indication is large non-toxic MNG).\n* Patients undergoing less than total thyroidectomy (e.g., lobectomy, subtotal thyroidectomy).",{"count":166,"type":23},280,"1 Month","The prevalence of incidental thyroid cancer (ITC) in Graves' Disease (GD) patients undergoing thyroidectomy appears higher than historically believed, potentially exceeding 10% in large contemporary series, although significant variability exists. The presence of nodules is a strong predictor, while the roles of age, sex, and BMI require clarification. Most ITCs are papillary thyroid microcarcinoma(PTMCs) with generally favorable prognoses, but concerns about aggressiveness persist.\n\nThe purpose of the present study is to accurately evaluate the prevalence of incidental thyroid carcinoma (ITC), including microcarcinomas, in a prospectively enrolled cohort of patients undergoing total thyroidectomy for Graves' disease, utilizing standardized pathological examination protocols and secondary outcomes including predictors and histopathological characteristics.",[170,59],"Thyroid Cancer",[172],"Incidental thyroid cancer","2026-08-08",{"date":103,"type":36},{"date":176,"type":36},"2025-07-15",{"date":178,"type":23},"2027-01-15",{"name":180,"class":181},"Minia University","OTHER",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":192,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100641998","phase-3-study-to-determine-if-bhv-1300-is-effective-and-safe-in-adults-with-graves-disease-100641998","NCT07661056","Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease","A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease","Key Inclusion Criteria:\n\n1. Participants must have serologically confirmed Graves' disease as documented by presence of elevated autoantibodies\n2. Participants must have active hyperthyroidism due to Graves' disease\n\nKey Exclusion Criteria:\n\n1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter)\n2. History of treatment with radioactive iodine or thyroid surgery.\n3. Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within six weeks of the Baseline\u002FDay 1 Visit.\n4. Thyroid storm, i.e. severe thyrotoxicosis with evidence of systemic decompensation (e.g., Burch-Wartkofsky Point Scale of ≥ 45 or Japanese Thyroid Association category 1 or 2, with accompanying manifestations including hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, or hepatic failure) within 6 weeks of Screening.\n5. Have autoimmune disease other than Graves' disease requiring treatment\n6. Have moderate to severe thyroid eye disease (TED) and are expected to require immediate surgical intervention and\u002For are planning corrective surgery\u002Firradiation or medical therapy for TED during study participation.\n7. Are expected to require urgent or emergent thyroid surgery or ablation within six weeks of Baseline\u002FDay 1 or throughout the study.","70 Years",{"count":191,"type":23},300,[56],"The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid",[59],[31],"2026-08-05",{"date":198,"type":36},"2026-08-07",{"date":200,"type":36},"2026-06-26",{"date":202,"type":23},"2028-02",{"name":204,"class":43},"Biohaven Therapeutics Ltd.",30,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":24,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":228},"100472720","phase-4-preoperative-corticosteroids-in-autoimmune-thyroid-disease-100472720","NCT05435547","Preoperative Corticosteroids in Autoimmune Thyroid Disease","Randomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDisease","* Inclusion Criteria:\n\n  ■ Graves' disease or Hashimoto's disease with positive thyroid autoantibodies (TgAb, TPO, TSI, and\u002For TRAb) undergoing total thyroidectomy for their disease.\n* Exclusion Criteria:\n\n  * Pediatric patients \\\u003C 18\n  * Prior treatment with RAI\n  * Prior neck surgeries\n  * Known diagnosis of thyroid cancer\n  * Diabetic patients on medications\n  * A history of adverse reactions to corticosteroids.\n  * Patients on any immunosuppressive regimen (such as organ transplant patients or patients treated for other autoimmune conditions). This includes patients with recent history of steroid therapy, or a history of adverse reactions to corticosteroids.",{"count":214,"type":23},76,[216],"PHASE4","This study proposes to randomize patients about to undergo surgery for their autoimmune, inflammatory thyroid disease, and determine if a short course of corticosteroids decreases the inflammation of the gland and makes surgery less difficult.",[59,219],"Hashimoto Disease","2026-08-03",{"date":196,"type":36},{"date":223,"type":36},"2023-06-16",{"date":225,"type":23},"2027-06-30",{"name":227,"class":181},"Indiana University",3,{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":239,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100616454","phase-1-nexus-study-a-study-to-test-single-and-multiple-doses-of-mer511-given-to-adults-with-graves-disease-100616454","NCT07305818","NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease","A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease","Inclusion Criteria:\n\n1. Adults 18 to 65 years of age, inclusive, at the time of signing the ICF\n2. Documented GD diagnosis,\n3. Receiving stable dose of ATD (Antithyroid drug)\n4. Body weight at least 50 kg (110 lb) and body mass index (BMI) 18.0-35.0 kg\u002Fm2, inclusive\n5. Women of childbearing potential must agree to use highly effective contraceptive methods\n6. Men with partners of childbearing potential or who are pregnant must agree to use a condom or strict abstinence\n7. Signed informed consent to participate in the study\n8. Willingness and ability, in the opinion of the investigator, to comply with protocol requirements and restrictions (eg, dosing, schedule of assessments).\n\nExclusion Criteria:\n\n1. History of:\n\n   1. total thyroidectomy.\n   2. History of hyperthyroidism not caused by GD (eg, toxic adenoma, toxic multinodular goiter).\n   3. History of thyroid storm.\n   4. History of agranulocytosis, anemia, leukopenia, thrombocytopenia, vasculitis, or liver toxicity due to prior ATD therapy Treatment with RAI therapy within 12 months prior to Screening\n2. Likely to require definitive treatment for GD (RAI therapy or thyroidectomy) during the study, based on GD history and anticipated prognosis.\n3. Use of levothyroxine, desiccated thyroid extract, or T3 at any dose within 6 weeks prior to Screening.\n4. Current active or chronic moderate-to-severe TED per EUropean Group On Graves' Orbitopathy (EUGOGO) criteria as judged by the investigator at Screening\n5. History of TED-directed medical treatment (including IV\u002Foral steroids, immunosuppressants, or teprotumumab), surgical treatment, and\u002For orbital radiation within 3 months prior to Screening, or per required prohibited concomitant therapy washout criteria in the protocol (whichever is longer)\n6. Major surgery or use of iodinated contrast within 3 months prior to planned IMP dosing.\n7. Active systemic autoimmune disease requiring treatment that causes undue risk in the opinion of the investigator.\n8. History of cardiovascular, respiratory, renal, gastrointestinal, endocrinological (other than GD), hematological, immunodeficiency, or neurological disorders that may constitute a risk when taking the IMP or interfere with data interpretation.\n9. History of liver disease\n10. Pregnant, breastfeeding, or planning to become pregnant during the study\n11. Treatment with prohibited medications prior to planned IMP dosing or likely to require prohibited concomitant therapy during the study\n12. Live vaccine(s) or mRNA vaccine(s) within 1 month prior to IMP dosing, or plans to receive such vaccines during the study\n13. Treatment with any investigational drug within within 3 months or 5 half-lives (whichever is longer) prior to enrollment\n14. Total IgG level \\\u003C700 mg\u002FdL at Screening\n15. Any of the following at Screening (confirmed by single repeat measurement, if deemed necessary):\n\n    * ALT or AST \\>1.5 × ULN\n    * Total bilirubin \\>1.5 × ULN\n16. Estimated glomerular filtration rate (eGFR) \\\u003C75 mL\u002Fmin\u002F1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation\n17. Positive result for HIV antibody, HBsAg, or hepatitis C antibody with detectable viral RNA levels at Screening\n18. Positive drug screen or positive test for alcohol\n19. 12-lead ECG demonstrating any of the following at Screening:\n\n    * QTcF interval \\>450 ms\n    * QRS interval \\>120 ms\n    * PR interval \\>220 ms\n20. Blood pressure measurements demonstrating any of the following at Screening:\n\n    * Systolic blood pressure ≥140 mmHg\n    * Diastolic blood pressure ≥90 mmHg\n21. Heart rate \\\u003C45 bpm or \\>100 bpm\n22. Donated more than 500 mL of blood in the 2 months prior to signing the ICF\n23. Current enrollment or past participation within 3 months or 5 half-lives (whichever is longer) prior to signing the ICF in any other clinical trial involving an IMP\n24. Refusal to adhere to lifestyle considerations as defined in the protocol\n25. Employee of the investigator, clinic, or sponsor with direct involvement in the proposed study or other studies under the direction of the investigator or clinic, as well as family members of the employee or investigator\n26. Any other conditions that, in the opinion of the investigator or the sponsor, could interfere with participation in or completion of the study","65 Years",{"count":238,"type":23},100,[240],"PHASE1","The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.",[59],[29,31,244,245,246,247,248,148],"Basedow disease","Exophthalmic goitre","TSHR","Autoimmune","Anti-thyroid drugs","2026-07-31",{"date":220,"type":36},{"date":252,"type":36},"2025-12-19",{"date":254,"type":23},"2028-07-24",{"name":256,"class":43},"Merida Biosciences",9,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":236,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":269,"conditions":270,"keywords":276,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":93},"100624764","telehealth-music-therapy-for-adults-with-endocrine-disorder-and-depression-100624764","NCT07413874","Telehealth Music Therapy for Adults With Endocrine Disorder and Depression","Telehealth Music Therapy for Adults With Endocrine System Based Autoimmune Disease and a Depressive Disorder: An Intervention Development Study","Inclusion Criteria:\n\n* self-reported depression\n* self-reported autoimmune endocrine disease\n* 18-65 years of age\n* have a device that supports the Zoom platform (camera and audio)\n\nExclusion Criteria:\n\n* intellectual or developmental disability\n* no auto-immune disease\n* no depression\n* lack of access to device\n* under the age of 18 years\n* over the age of 65 years",{"count":266,"type":23},10,[268],"NA","The goal of this clinical trial is to explore if a telehealth music therapy intervention helps with quality of life, depression symptoms, anxiety symptoms. It will also explore the participants' relationship to music. The main questions it aims to answer are:\n\n* Refine and tailor the music therapy intervention to fit the specific needs of adults living with an autoimmune disease and depression.\n* Examine the feasibility of the study protocol to support a future full-scale trial\n* Examine how music therapy impacts quality of life, depression symptoms, and anxiety symptoms\n* Explore how music therapy impacts one's relationship to music\n\nParticipants will:\n\n* have a short interview to fill out a questionnaire with some basic information, answers about depression, quality of life, and potential anxiety, and a question about how they feel about music at the start and end of the sessions\n* attend 8 weekly sessions, approximately 30-45 minutes each, with a board certified music therapist over telehealth\u002FZoom\n* answer a few questions about the music therapy intervention",[271,219,59,272,273,274,275],"Type 1 Diabetes","Addison Disease","Autoimmune Polyglandular Syndrome Type III","Depression","Endocrine System Diseases",[277,278,279,280,281,282,283,284],"type 1 diabetes","music therapy","behavioral health","psychosocial","diabetes","behavioral intervention","quality of life","telehealth","2026-07-29",{"date":38,"type":36},{"date":288,"type":36},"2026-07-16",{"date":290,"type":23},"2026-12-31",{"name":292,"class":181},"Appalachian State University",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":236,"enrollmentInfo":300,"targetDuration":4,"studyType":24,"phases":302,"briefSummary":303,"conditions":304,"keywords":305,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":317},"100591455","phase-1-study-of-bhv-1300-in-graves-disease-100591455","NCT06980649","Study of BHV-1300 in Graves' Disease","An Open-Label Biomarker Study of BHV-1300 in Graves' Disease","Key Inclusion Criteria:\n\n1\\. Participants must have serologically confirmed Graves' Disease.\n\nKey Exclusion Criteria:\n\n1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and\u002For history of thyroid storm within six weeks of the Baseline visit.\n2. History of treatment with radioactive iodine or thyroid surgery.",{"count":301,"type":23},15,[240],"The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.",[59],[148,306,307,308,309,310],"hyperthyroidism","anti thyroid drug","thyroid disease","autoimmune diseases","endocrine system diseases",{"date":249,"type":36},{"date":313,"type":36},"2025-08-21",{"date":315,"type":23},"2027-09",{"name":204,"class":43},18,{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":24,"phases":327,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":341},"100646925","phase-2-evaluation-of-yb-101-for-safety-tolerability-pharmacokinetics-and-efficacy-in-graves-disease-100646925","NCT07682896","Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease","A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease","Inclusion Criteria:\n\n* Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment\n* Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening\n* Additional inclusion criteria are defined in the protocol\n\nExclusion Criteria:\n\n* Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy\n* Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening\n* Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening\n* History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit\n* Pregnant or lactating women\n* Additional exclusion criteria are defined in the protocol",{"count":326,"type":23},232,[26],"This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.\n\nThe study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2.\n\nParticipants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.",[29],[331,29,31,148,332],"Graves'","TSH receptor antibodies","2026-07-27",{"date":335,"type":36},"2026-07-28",{"date":62,"type":36},{"date":338,"type":23},"2029-09",{"name":340,"class":43},"Yarrow Bioscience, Inc.",28,{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":350,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":351,"targetDuration":353,"studyType":78,"phases":4,"briefSummary":354,"conditions":355,"keywords":358,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":93},"100648139","screening-classification-and-outcome-prediction-ensemble-using-orbital-mri-for-thyroid-eye-disease-the-ted-scope-national-multicenter-registry-study-100648139","NCT07716397","Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study","Construction and Optimization of a Multimodal Orbital MRI-AI Model and Its Application in Thyroid Eye Disease: A National Multicenter Registry Study","TED-SCOPE-MR","Inclusion Criteria:\n\n* TAO patient group\n\n  * Age between 18 and 75 years old, regardless of gender.\n\n    * Patients with thyroid eye disease who meet the disease staging and grading criteria specified in diagnostic guidelines such as those of Bartley, CAS, and EUGOGO.\n\n      * The patient has planned or received thyroid-related treatment, and the condition is relatively stable.\n\n        * Voluntarily participate in this study and sign the informed consent form.\n\nControl group:\n\n① Healthy volunteers matched with the TAO group in terms of age and gender.\n\n② Voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* TAO patient group:\n\n  * Pregnant or lactating women.\n\n    * Patients with other orbital lesions.\n\n      ③ Having contraindications for MRI examination (such as non - compatible metal implants in the body, claustrophobia, etc.).\n\n      ④ The patient has previously received orbital radiotherapy or orbital surgery (except for patients who need to collect tissue specimens).\n\n      ⑤ Comorbid with other severe systemic diseases (such as uncontrolled heart failure, liver and kidney failure) or mental illnesses, and unable to cooperate to complete the study.\n\n      ⑥ Participated in other clinical trials that may interfere with the results of this study within 3 months.\n\nControl group:\n\nSame as the exclusion criteria 1 - 6 for the TAO patient group",true,{"count":352,"type":23},1200,"18 Months","The goal of this observational study is to prospectively validate the efficacy of an AI multimodal model constructed based on multi - sequence orbital MRI in the diagnosis, activity and severity assessment, and prognosis prediction of thyroid - associated ophthalmopathy (TAO) in real - world clinical scenarios. The main questions it aims to answer are:\n\nCan AI models accurately assess the presence, activity, and severity of Thyroid-Associated Orbitopathy (TAO)? Can AI models predict the prognosis of TAO? Researchers will compare the diagnostic accuracy of the AI model for TAO patients and healthy subjects to evaluate its diagnostic performance.\n\nParticipants will undergo a standardized, study - specific multimodal orbital MRI scan (sequences include T1WI, T2WI, STIR, and research sequences such as Magic, IDEAL - IQ, DWI, ASL, CEST). And will systematically acquire ocular ultrasound images from TED patients (active and inactive stages), non-TED ophthalmic disease controls, and healthy volunteers. AI-driven deep learning techniques (convolutional neural networks) will be applied to achieve automatic segmentation of key structures (extraocular muscles, optic nerve, lacrimal gland, and retrobulbar soft tissue). High-throughput radiomic features encompassing morphological parameters and gray-level texture patterns will be extracted. Machine learning algorithms will then be employed to construct objective prediction models for TED screening and activity staging, with MRI findings and CAS scores serving as the reference standards for external validation.",[356,59,357],"Graves Ophthalmopathy","Thyroid Associated Ophthalmopathies",[359],"TED","2026-07-20",{"date":362,"type":36},"2026-07-21",{"date":364,"type":36},"2026-01-01",{"date":366,"type":23},"2028-12-31",{"name":368,"class":181},"Shanghai Changzheng Hospital",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":301},"100591761","phase-2-a-study-to-investigate-the-efficacy-and-safety-of-rilzabrutinib-in-adult-participants-with-graves-disease-100591761","NCT06984627","A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","Inclusion Criteria:\n\n* Participants who have a confirmed diagnosis of Graves' disease with active hyperthyroidism, with or without active Graves' orbitopathy at the time of screening.\n* A subset of participants will have a diagnosis of active Graves' orbitopathy, as confirmed by ophthalmic exam at screening and a clinical activity score (CAS) ≥3 for the most severely affected eye, and associated with one or more of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, proptosis ≥2 mm, and\u002For intermittent or constant diplopia.\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by Graves' disease (eg, hyperthyroidism due to toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis).\n* History of thyroid storm or at high risk of developing thyroid storm as determined by evaluating clinician.\n* Enlarged thyroid goiter causing upper airway obstruction and\u002For requiring surgical intervention during the study period.\n* For participant with Graves' orbitopathy, requires immediate surgical ophthalmological intervention or is planning corrective surgery\u002Firradiation during the course of the study.\n* Sight threatening Graves' orbitopathy or decreased visual acuity due to optic neuropathy within the last 6 months.\n* Corneal decompensation unresponsive to medical management.\n* Onset of Graves' orbitopathy symptoms \\>9 months prior to baseline.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":205,"type":23},[26],"This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.\n\nStudy details include:\n\n* Screening period (up to 4 weeks).\n* Treatment period (up to 16 weeks).\n* Follow-up period (4 weeks). The number of visits will be up to 13.",[29],"2026-07-06",{"date":382,"type":36},"2026-07-07",{"date":384,"type":36},"2025-09-02",{"date":386,"type":23},"2026-09-23",{"name":388,"class":43},"Sanofi",{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":396,"maxAge":4,"enrollmentInfo":397,"targetDuration":398,"studyType":78,"phases":4,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":415,"locationsCount":93},"100594320","evaluating-an-ai-tool-for-detecting-thyrotoxic-states-100594320","NCT07017907","Evaluating an AI Tool for Detecting Thyrotoxic States","Performance Evaluation of the Software Medical Device to Detect the Thyrotoxic State in Patients With Hyperthyroidism","Inclusion Criteria:\n\n* Adults aged 22 years or older, regardless of sex.\n* Individuals who are newly diagnosed with Graves' disease or currently undergoing treatment for it.\n* Individuals who have received sufficient explanation about the investigational software and are able to use it appropriately.\n* Individuals who voluntarily agree to participate in the study and have signed informed consent, either directly or via a legally authorized representative.\n\nExclusion Criteria:\n\n* Individuals with cardiac conditions such as arrhythmia or heart failure.\n* Individuals taking medications that significantly affect heart rate, including antiarrhythmics or antihistamines. (Intermittent short-acting beta-blockers are allowed.)\n* Pregnant or breastfeeding individuals, or those planning pregnancy during the study period or not using appropriate contraception.\n* Individuals with significant comorbidities that interfere with follow-up or study compliance.\n* Individuals with severe psychiatric disorders, substance use disorder, or alcohol dependence.\n* Individuals deemed ineligible at the discretion of the investigator for safety or ethical concerns.","22 Years",{"count":301,"type":23},"12 Weeks","This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.",[59,401],"Hyperthyroidism\u002FThyrotoxicosis",[403,31,404,405,406,407,408],"Graves disease","Thyrotoxicosis","Artificial intelligence","Heart rate","SaMD","wearable device","2026-05-28",{"date":411,"type":36},"2026-06-01",{"date":413,"type":36},"2026-01-09",{"date":290,"type":23},{"name":416,"class":43},"THYROSCOPE INC.",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":424,"targetDuration":4,"studyType":24,"phases":426,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":93},"100618596","early-phase-1-in-vivo-car-t-for-refractory-graves-disease-100618596","NCT07333677","In Vivo CAR-T for Refractory Graves' Disease","A Safety and Efficacy Study of in Vivo CAR-T (HN2301) for Refractory Graves' Disease","Inclusion Criteria (Participants must meet all of the following criteria to be eligible for this study):\n\n* Age 18-75 years (inclusive), male or female.\n* Refractory Graves' disease, defined as meeting at least one of the following: a) Continuous antithyroid drug (ATD) therapy for ≥3 years without achieving criteria for ATD discontinuation; b) Meeting criteria for ATD discontinuation but experiencing ≥2 relapses after ATD withdrawal.\n* Positive serum TRAb.\n* Willing to use effective contraception for 12 months after study drug administration.\n* Voluntarily agrees to participate in the study, has signed the informed consent form, and is able to comply with study procedures and follow-up requirements.\n\nExclusion Criteria (Participants meeting any of the following criteria will be excluded from the study):\n\n* History of severe drug allergy or known allergic predisposition.\n* Presence or suspected presence of uncontrolled active infection.\n* History of major organ transplantation (e.g., heart, lung, liver, kidney) or bone marrow\u002Fhematopoietic stem cell transplantation.\n* Presence of significant heart disease, such as angina, myocardial infarction, heart failure, or clinically significant arrhythmias.\n* Receipt of any mRNA-LNP product or other lipid nanoparticle (LNP)-based therapy within the past 2 years.\n* Receipt of a live vaccine within 30 days prior to screening.\n* History of malignant tumors.\n* Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA above the detection limit; positive hepatitis C virus (HCV) antibody with detectable HCV RNA; positive human immunodeficiency virus (HIV) antibody; or positive syphilis test.\n* Presence of psychiatric disorders or severe cognitive impairment.\n* Hematologic dysfuction at screening, defined as any of the following: a. Neutrophil count \\\u003C 1.8 × 10⁹\u002FL, b. Hemoglobin \\\u003C 110 g\u002FL, c. Platelet count \\\u003C 50 × 10⁹\u002FL\n* Impaired liver function, defined as any of the following: Alanine aminotransferase (ALT) \\> 3 × ULN, Aspartate aminotransferase (AST) \\> 3 × ULN, Total bilirubin \\> 2.5 × ULN.\n* Impaired renal function: creatinine clearance rate (CrCl) \\\u003C 60 mL\u002Fmin (Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) \\\u003C 55%.\n* Coagulation abnormalities, defined as either: International normalized ratio (INR) \\> 1.5 × ULN, Prothrombin time (PT) \\> 1.5 × ULN\n* Pregnant or breastfeeding women.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.",{"count":425,"type":23},5,[427],"EARLY_PHASE1","Graves' disease is an autoimmune thyroid disorder characterized by the production of autoantibodies against the thyroid-stimulating hormone receptor (TRAb), leading to excessive thyroid hormone secretion and systemic manifestations. A subset of patients develop refractory disease, failing to achieve durable remission despite prolonged antithyroid therapy.\n\nThis study aims to evaluate the safety and efficacy of HN2301, an in vivo CAR-T therapy in which host T lymphocytes are engineered and transformed to functional CAR-T cells via CD8 antibody-coated LNP delivery of CD19 CAR-mRNA. Participants with refractory Graves' disease will receive three to five administrations of HN2301 and will be regularly monitored for changes in thyroid function, TRAb levels, clinical response, and treatment-related adverse events. The study will provide preliminary evidence on whether HN2301 can induce sustained remission of refractory Graves' disease.",[29],[431,432,433],"refractory Graves' disease","TSH receptor antibody","in vivo CAR-T","2026-03-18",{"date":436,"type":36},"2026-03-19",{"date":438,"type":36},"2026-01-29",{"date":440,"type":23},"2027-12",{"name":442,"class":181},"Shanghai Zhongshan Hospital",{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":350,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":78,"phases":4,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":93},"100629903","systemic-inflammation-thyroid-autoimmunity-and-neuroretinal-changes-in-graves-disease-100629903","NCT07480720","Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease","Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n\nDiagnosis of Graves' disease (for the patient group)\n\nNo known thyroid disease in healthy control participants\n\nAvailability of optical coherence tomography (OCT) measurements and laboratory data\n\nTime interval between OCT examination and blood sampling ≤ 10 days\n\nExclusion Criteria:\n\n* Presence of glaucoma, optic neuropathy, or retinal vascular diseases\n\nMacular diseases, uveitis, or severe refractive error (high myopia \\>6 diopters)\n\nDiabetic retinopathy\n\nHistory of previous intraocular surgery\n\nHistory of active infection, malignancy, or systemic inflammatory disease\n\nPoor-quality OCT measurements (segmentation errors or low signal strength)",{"count":238,"type":23},"This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.",[59,356],[403,454,455,456,457,458],"Thyroid autoimmunity","Systemic inflammation","Optical coherence tomography","Retinal nerve fiber layer","Graves ophthalmopathy","2026-03-14",{"date":434,"type":36},{"date":462,"type":36},"2026-03-01",{"date":464,"type":23},"2026-05-01",{"name":466,"class":181},"Elazıg Fethi Sekin Sehir Hastanesi",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":24,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":93},"100614981","phase-1-a-study-of-genssci098-in-subjects-with-graves-disease-100614981","NCT07286656","A Study of GensSci098 in Subjects With Graves' Disease","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Voluntary signed informed consent.\n* Confirmed diagnosis of diffuse toxic goiter (Graves' disease).\n* Abnormal thyroid function tests (e.g., elevated T4, and suppressed TSH).\n* No prior or recent use of antithyroid medications (discontinued for at least 4 weeks).\n* Female participants must be postmenopausal, surgically sterile, or using a highly effective method of contraception.\n* Male participants must agree to practice abstinence, use a highly effective method of contraception， or have undergone vasectomy.\n* Ability to comply with the follow-up schedule and understand and adhere to the study requirements.\n\nExclusion Criteria:\n\n* Non-diffuse toxic goiter-induced hyperthyroidism.\n* Previous radioactive iodine treatment or thyroid surgery.\n* History or risk of thyroid storm.\n* Use of thyroid hormone medications within the past 6 weeks.\n* accompanied by active thyroid eye disease.\n* Thyroid eye disease treated with radiation\u002Fsurgery,or need for urgent surgery surgical or medical intervention.\n* Optic nerve lesions or corneal damage.\n* Use of steroids or immunosuppressants within the past 3 months,or those who have used biologics within 6 months\n* Inability to quit smoking during the study.\n* Allergy to the study drug or monoclonal antibodies.\n* Participation in another clinical trial within the past 3 months.\n* Abnormal electrocardiogram.\n* Significant hepatic or renal dysfunction.\n* Pregnancy,breastfeeding,or positive pregnancy test.\n* Positive for HIV,syphilis,hepatitis B,or hepatitis C.\n* History of drug or substance abuse.\n* Other autoimmune diseases requiring treatment.\n* History of malignant tumors.\n* Splenectomy or major surgery within the past 6 months.\n* Severe cardiovascular,pulmonary,hepatic,renal,neurological,or hematological diseases.\n* Other conditions deemed unsuitable by investigators.",{"count":475,"type":23},24,[240],"To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease",[479,480,481,59],"Safety","Tolerability","GenSci098","2026-02-13",{"date":484,"type":36},"2026-02-17",{"date":486,"type":36},"2025-11-21",{"date":488,"type":23},"2027-03-18",{"name":490,"class":43},"Changchun GeneScience Pharmaceutical Co., Ltd.",{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":24,"phases":498,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":93},"100624515","impact-of-thyroid-hormones-on-human-glucose-and-energy-metabolism-100624515","NCT07410637","Impact of Thyroid Hormones on Human Glucose and Energy Metabolism","Inclusion Criteria:\n\n* patients with initial diagnosis of graves disease OR\n* patients with initial diagnosis of thyroid carcinoma\n\nExclusion Criteria:\n\n* contraindications for oral glucose tolerance test\n* Diabetes mellitus\n* Fasting glucose level ≥ 200 mg\u002FdL\n* Exogenous insulin administration with action at the time of the test\n* Current disease with activation of stress hormones\n* Post-aggressive metabolism\n* Acute infectious disease",{"count":22,"type":23},[268],"The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism.\n\nPatients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.",[59,170],[502,503,504,505,506,306],"thyroid hormones","glucose metabolism","lipid metabolism","graves disease","thyroid cancer","2026-02-12",{"date":482,"type":36},{"date":510,"type":36},"2026-02-04",{"date":512,"type":23},"2031-06",{"name":514,"class":181},"University of Ulm",{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":522,"maxAge":523,"enrollmentInfo":524,"targetDuration":4,"studyType":24,"phases":525,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":93},"100621318","phase-2-impact-of-vitamin-d-therapy-on-thyroid-function-and-antibody-levels-in-pediatric-graves-disease-100621318","NCT07369063","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility Trial","Inclusion Criteria:\n\n* All new pediatric participants aged 9-17 years with a new diagnosis of GD who will be started on methimazole, will be offered to participate at the time of diagnosis.\n* Biochemical features include:\n* Suppressed TSH \\\u003C0.1.\n* Elevated T3\n* Elevated Free T4\n* Elevated T4\n* Positive TSI or TRAb. The presence of antibodies is diagnostic.\n* Our study will offer enrollment to non-English speaking participants\n\nExclusion Criteria:\n\n* Initial hydroxy vitamin D levels \\>80 ng\u002FmL\n* Hypocalcemia, corrected calcium based on albumin \\\u003C8.4 mg\u002FdL\n* Hypercalcemia, corrected calcium based on albumin \\>10.5 mg\u002FdL\n* Conditions that affect vitamin D metabolism such as: malabsorption, chronic kidney or liver disease, nephrocalcinosis, hyperparathyroidism\n* Current use of medications which are known to affect thyroid function or vitamin D metabolism such as thyroid hormone replacement, corticosteroids, anticonvulsants\n* Allergy to vitamin D or methimazole\n* Diagnosis of Hashitoxicosis or thyrotoxicosis (both TSH receptor antibody (TRAb) and thyroid-stimulating immunoglobulin (TSI) levels are negative)\n* Participants under the age of 9 years at the time of diagnosis\n* Pregnant participants\n* Active or uncontrolled infections, other significant medical conditions deemed by the investigator to interfere with study participation or pose undue risk to the participant.","9 Years","17 Years",{"count":205,"type":23},[26],"The goal of this randomized pilot feasibility clinical trial is to determine the feasibility of implementing a protocol for a larger trial to assess the effects of high-dose vitamin D supplementation in pediatric patients (9-17 years old) newly diagnosed with Graves' disease. The main questions it aims to answer are:\n\nWhat are the recruitment and adherence rates for a larger trial using this protocol? Is the data collection process complete and robust enough for a larger trial? What are the potential barriers to implementing a larger-scale trial? Researchers will compare vitamin D supplementation plus standard methimazole therapy to methimazole therapy alone (with participants permitted to take up to 1000 International Units of vitamin D2 daily) to explore potential effects on thyroid hormone and antibody levels.\n\nParticipants will:\n\nBe randomized to either the intervention or control group. Take study medications (vitamin D or placebo) as directed. Attend regular study visits for blood tests and clinical assessments. Complete medication logs.",[59,29,31],[529,505,306],"vitamin d","2026-01-23",{"date":532,"type":36},"2026-01-27",{"date":534,"type":36},"2025-08-01",{"date":536,"type":23},"2027-02-28",{"name":538,"class":181},"Northwell Health",{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":555,"leadSponsor":556,"locationsCount":93},"100613035","early-phase-1-allogeneic-anti-cd19bcma-car-t-for-refractory-graves-disease-100613035","NCT07261345","Allogeneic Anti-CD19\u002FBCMA CAR-T for Refractory Graves' Disease","The Safety and Efficacy of Allogenic Anti-CD19\u002FBCMA CAR-T Cell Therapy for Refractory Graves' Disease","Inclusion Criteria (Participants must meet all of the following inclusion criteria to be eligible for this study):\n\n* Refractory Graves' disease, defined as meeting at least one of the following: a) Continuous treatment with antithyroid drugs (ATDs) for ≥3 years without achieving criteria for drug discontinuation. b) Meeting criteria for drug discontinuation but experiencing ≥2 relapses after withdrawal.\n* Positive serum TRAb.\n* Willing to voluntarily participate in this clinical study, able to sign informed consent, and compliant with follow-up requirements.\n\nExclusion Criteria (Participants will be excluded if any of the following conditions apply):\n\n* History of severe drug allergies or allergic constitution.\n* Presence or suspected presence of uncontrolled or active infections (including bacterial, fungal, viral, or other pathogens) requiring systemic or intravenous treatment.\n* Presence of central nervous system disorders (including epilepsy, psychosis, cerebrovascular accident, encephalitis, CNS vasculitis, etc).\n* Presence of clinically significant heart diseases (e.g., angina pectoris, myocardial infarction, heart failure, severe arrhythmias, etc).\n* Subjects with congenital immunoglobulin deficiency.\n* Subjects with malignancy (current or past), except for conditions deemed cured and with no risk of recurrence based on investigator assessment.\n* Positive viral serology, including any of the following: Hepatitis B surface antigen (HBsAg)-positive, or hepatitis B core antibody (HBcAb)-positive with HBV DNA above the upper limit; Hepatitis C virus (HCV) antibody-positive with detectable HCV RNA; Human immunodeficiency virus (HIV) antibody-positive; Positive syphilis test.\n* Severe psychiatric disorder or significant cognitive impairment that may affect compliance.\n* Hematologic dysfunction, including: a) White blood cell count \\\u003C 3.5 × 10⁹\u002FL; b) Neutrophil count \\\u003C 1.8 × 10⁹\u002FL; c) Hemoglobin \\\u003C 110 g\u002FL.\n* Hepatic dysfunction, defined as any of the following: Alanine aminotransferase (ALT) \\> 3 × ULN; Aspartate aminotransferase (AST) \\> 3 × ULN; Total bilirubin (TBIL) \\> 2.5 × ULN.\n* Renal dysfunction: creatinine clearance rate (CrCl) \\\u003C 60 mL\u002Fmin (Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) \\\u003C 55%.\n* Coagulation abnormalities, defined as either: International normalized ratio (INR) \\> 1.5 × ULN; Prothrombin time (PT) \\> 1.5 × ULN.\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Pregnant or breastfeeding women, or women planning to become pregnant.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.",{"count":44,"type":23},[427],"Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and systemic complications, as well as thyroid eye disease and pretibial myxedema in some cases. Patients with refractory Graves' disease often fail to achieve durable remission despite prolonged antithyroid medication.\n\nThis study aims to evaluate the safety and efficacy of RD06-05, an allogeneic dual CD19\u002FBCMA CAR-T therapy, in participants with refractory Graves' disease, and will provide preliminary evidence on whether dual-targeting CAR-T therapy can induce sustained remission of refractory Graves' disease.",[29],[551,432,431],"CAR-T",{"date":553,"type":36},"2026-01-05",{"date":252,"type":36},{"date":440,"type":23},{"name":442,"class":181},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":566,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":580,"locationsCount":93},"100596521","thyroid-artery-goitre-embolization-trial-a-pilot-study-investigating-thyroid-artery-embolisation-as-a-treatment-for-large-thyroid-nodules-100596521","NCT07046546","Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules","Thyroid ARtery Goitre Embolization Trial: A Service Introduction and Safety Assessment","TArGET","Inclusion Criteria:\n\n* The participant may enter the study if ALL of the following apply:\n\n  * Adults over 18 years of age willing and able to give informed consent.\n  * Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).\n  * Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre\n  * TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.\n  * FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.\n  * No enlarged \u002F suspicious neck lymphadenopathy on ultrasound.\n  * Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and \u002F or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.\n  * Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.\n\nExclusion Criteria:\n\n* The participant may enter the study if ALL of the following apply:\n\n  * Adults over 18 years of age willing and able to give informed consent.\n  * Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).\n  * Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre\n  * TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.\n  * FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.\n  * No enlarged \u002F suspicious neck lymphadenopathy on ultrasound.\n  * Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and \u002F or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.\n  * Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.",{"count":266,"type":23},[268],"Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Not all patients are suitable however for these treatments, some lumps are too large, or the patients are not fit enough for surgery.\n\nThyroid artery embolization (TAE) is a new minimally invasive technique (smaller incisions \u002F cuts and shorter recovery time) performed under light sedation. It is used by other European Thyroid Centres, but it hasn't been used in the UK. Embolization means arteries supplying the thyroid gland are blocked by injecting small occlusive particles, like very fine grains of sand that can get stuck in small spaces, preventing blood from passing through. Blocking the thyroid arteries causes the gland to shrink. This provides symptom relief or controls an overactive gland.\n\nWe aim to undertake a TAE pilot study to explore the safety of TAE in a UK patient population. We are planning to recruit 10 eligible patients. We will also collect additional data (for example on pain, effectiveness, cost and health related quality of life) to inform a future larger trial comparing TAE to other treatment options.",[569,59,570],"Thyroid Nodule (Benign)","Goitre",[572,573],"Thyroid artery embolisation","Benign thyroid nodules","2025-12-23",{"date":576,"type":36},"2025-12-24",{"date":578,"type":36},"2025-09-29",{"date":133,"type":23},{"name":581,"class":582},"Royal Berkshire NHS Foundation Trust","OTHER_GOV",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":236,"enrollmentInfo":590,"targetDuration":4,"studyType":24,"phases":592,"briefSummary":593,"conditions":594,"keywords":595,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":93},"100539859","the-impact-of-person-centred-care-pcc-in-graves-disease-100539859","NCT06309316","The Impact of Person Centred Care (PCC) in Grave's Disease","The Impact of Person Centred Care (PCC) on Mental Outcome and Work Ability in Graves' Disease - the GRAves CarE (GRACE) PCC Project","Inclusion Criteria:\n\n* Age 18-65 years\n* First time Graves' diseases with elevated FT4 and\u002For FT3 and positive TSH receptor antibody (TRAb)\n\nExclusion Criteria:\n\n* Patients that cannot attend to the protocol\n* Patients with moderate-severe\u002F severe Graves' eye disease",{"count":591,"type":23},220,[268],"Mental fatigue (MF) is prevalent after Graves' disease (GD), which is the most common form of hyperthyroidism. We have reported that 38% of patients, compared to 11% of control subjects, suffer from MF more than 1 year after successfully reversing of their hyperthyroidism and that MF is an entity of its own, separated from MF combined with anxiety or depression. The brain pathophysiology is unknown and there is no medical treatment, which requires patients to simply adapt to the situation. In the new national guideline for hyperthyroidism (Jan 2023), rehabilitation is recommended, but currently rarely offered to these patients. The problem is significant for patients, as illustrated by frequent media appeals. In this project, we hypothesise that person-centred care (PCC), which promotes positive coping strategies and increases self-efficacy by engaging patients as partners in their own care, improves MF, reduces sick leave, and lowers the recurrence rate of GD. In two work packages (WP), we will:\n\nWP1 Evaluate the effect of PCC eHealth intervention (telephone and digital platform) as an add-on to usual care vs usual care alone in a randomized controlled trial (RCT) of 220 patients on self-efficacy, days of sick-leave (composite score as primary outcome), MF, recurrence rate of disease, coping strategies, perceived stress, quality of life (QoL) and personality.\n\nWP2 Investigate the cost-effectiveness of the intervention\n\nPatients with GD have impaired long-term QoL. PCC could improve long-term outcomes of this autoimmune disease and may apply to other patient groups. This is in line with the societal aim to reduce mental illness.",[59],[596,597,598,599,600],"Person Centred Care","Mental fatigue","cost-effectiveness","self-efficacy","eHealth","2025-11-17",{"date":486,"type":36},{"date":604,"type":36},"2024-03-25",{"date":606,"type":23},"2030-01-30",{"name":608,"class":582},"Vastra Gotaland Region",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":617,"enrollmentInfo":618,"targetDuration":4,"studyType":24,"phases":620,"briefSummary":621,"conditions":622,"keywords":623,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":93},"100526398","course-for-brain-fatigue-after-graves-disease-controlled-study-100526398","NCT06134219","Course for Brain Fatigue After Graves' Disease Controlled Study","A Mental Fatigue Course to Graves' Disease Patients With Mental Fatigue -a Randomized Controlled Study","MF-Course","Inclusion Criteria:\n\n* 18-72 years old\n* 15-72 months since first Graves' diagnosis\n* high free thyroxin and thyroid antibodies (TRAb) at diagnosis\n* euthyroid the last 6 months normal thyroid hormone levels at inclusion\n* symptoms on MF in connection to Graves diagnosis\n* MF-scale ≥10.5 points\n\nExclusion criteria:\n\n* other diseases or situations that may be associated with mental fatigue (such as other active inflammatory disease, neurological disease)\n* pregnancy\n* lactation\n* assessment that the patient cannot follow the study protocol.","72 Years",{"count":619,"type":23},96,[268],"BACKGROUND. Mental fatigue (MF) is common in the most common form of hyperthyroidism, Graves' disease (GD). Clinically, MF is the primary mental symptom in patients with GD and is characterized by difficulties maintaining attention, exhaustion during cognitively demanding tasks, memory difficulties, irritability, and emotional lability. It may be the main contributing factor to the continued low quality of life in many patients with GD. MF can be measured with an MF score (MFS). The pathophysiology is unknown. There is no medical treatment, which requires patients to adapt to the situation.\n\nAIM. In this project, the investigators want to test the hypothesis that mental fatigue improves - with secondary benefits on mental capacity, quality of life (QoL), and function - in patients with persistent mental fatigue in GD, through an MF course as an addition to standard care, compared to patients who receive only standard care. The investigators also test the hypothesis that the MF course is a cost-effective intervention.\n\nMETHOD. In a randomized controlled study, the investigators evaluate the effect of the MF course compared to standard care only in 96 patients with persistent MF in GD. Markers of mental health, QoL, and activity capacity are evaluated at baseline, 3, 6, and 12 months after intervention\u002Finclusion. The primary outcome measure is MFS at 3 months.\n\nCLINICAL SIGNIFICANCE. Patients report feeling neglected by healthcare for decades, and healthcare professionals are frustrated by the lack of guidance. Patient organizations highlight the need for research; they want mental symptoms to be characterized as a consequence of thyroid disease, they demand biomarkers, specific treatments, and personalized care. Our research group is working to address the cause of MF in GD and also to alleviate the symptoms. The MF course may prove to be an important tool that can be quickly implemented in clinical practice, especially in primary care. Our involvement in regional\u002Fnational working groups will facilitate implementation in other units.\n\nIn this project, the investigators want to test the hypothesis that mental fatigue improves - with secondary benefits on mental capacity, quality of life (QoL), and function - in patients with persistent mental fatigue at GD, through an MF course as an addition to regular healthcare, compared to patients receiving only regular healthcare.",[59],[597],{"date":486,"type":36},{"date":626,"type":36},"2023-10-10",{"date":628,"type":23},"2027-05-10",{"name":608,"class":582}]